Hexagon Bio Raises $62 Million Series C Financing to Advance HEX-360 into the Clinic and Expand Pipeline of Antibody-Drug Conjugates with Novel Payload Mechanisms

Proceeds will support first-in-human study of HEX-360, a HER2-targeting ADC with a novel translation inhibitor payloadHexagon Bio anticipates ...